Gary J Jesmok, 76Raleigh, NC
Gary Jesmok Phones & Addresses
Raleigh, NC
Pinole, CA
Durham, NC
485 Carlston St, Richmond, CA 94805 510-2354485
1547 Santa Clara St, Richmond, CA 94804 510-2379630
Hercules, CA
Mentions for Gary J Jesmok
Publications & IP owners
Us Patents
Method Of Thrombolysis By Local Delivery Of Active Plasmin
US Patent:
6355243, Mar 12, 2002
Filed:
Nov 13, 1999
Appl. No.:
09/438331
Inventors:
Valery V. Novokhatny - Raleigh NC
Gary J. Jesmok - Richmond CA
Kyle A. Landskroner - Mill Valley CA
Kathryn K. Taylor - Apex NC
Thomas P. Zimmerman - Raleigh NC
Gary J. Jesmok - Richmond CA
Kyle A. Landskroner - Mill Valley CA
Kathryn K. Taylor - Apex NC
Thomas P. Zimmerman - Raleigh NC
Assignee:
Bayer Corporation - Pittsburgh PA
International Classification:
A61K 3848
US Classification:
424 9464, 424 9463, 435212, 435215, 435217
Abstract:
The invention provides an improved method of thrombolytic therapy by the direct admiistration of active plasmin to a clot site via catheter. An active, stable preparation of plasmin is provided, as is a process for activation and isolation of active plasmin.
Il-2 Selective Agonists And Antagonists
US Patent:
6955807, Oct 18, 2005
Filed:
May 13, 1999
Appl. No.:
09/341351
Inventors:
Armen B. Shanafelt - Carmel IN, US
Jeffrey M. Greve - Berkeley CA, US
Gary Jesmok - Richmond CA, US
Kenneth J. Lembach - Danville CA, US
Gayle D. Wetzel - Martinez CA, US
Jeffrey M. Greve - Berkeley CA, US
Gary Jesmok - Richmond CA, US
Kenneth J. Lembach - Danville CA, US
Gayle D. Wetzel - Martinez CA, US
Assignee:
Bayer Pharmaceuticals Corporation - Berkeley CA
International Classification:
C07K014/55
A61K038/20
C12N005/10
C12N015/26
C12N015/64
A61K038/20
C12N005/10
C12N015/26
C12N015/64
US Classification:
424 852, 530351, 536 235, 435 6952, 435 711, 435 712, 435471, 435325, 4352523, 43525411
Abstract:
The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
Method Of Thrombolysis By Local Delivery Of Reversibly Inactivated Acidified Plasmin
US Patent:
6964764, Nov 15, 2005
Filed:
May 10, 2002
Appl. No.:
10/143157
Inventors:
Thomas P. Zimmerman - Raleigh NC, US
Valery Novokhatny - Raleigh NC, US
Kyle A. Landskroner - Mill Valley CA, US
Gary J. Jesmok - Richmond CA, US
Kathryn K. Taylor - Apex NC, US
Valery Novokhatny - Raleigh NC, US
Kyle A. Landskroner - Mill Valley CA, US
Gary J. Jesmok - Richmond CA, US
Kathryn K. Taylor - Apex NC, US
Assignee:
Talecris Biotherapeutics, Inc. - Research Triangle Park NC
International Classification:
A61K038/48
C12N009/72
C12N009/68
C12N009/72
C12N009/68
US Classification:
424 9464, 435215, 435217
Abstract:
Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.
Method Of Thrombolysis By Local Delivery Of Reversibly Inactivated Acidified Plasmin
US Patent:
6969515, Nov 29, 2005
Filed:
Oct 25, 2002
Appl. No.:
10/280444
Inventors:
Gary J. Jesmok - Raleigh NC, US
Kyle A. Landskroner - Raleigh NC, US
Kyle A. Landskroner - Raleigh NC, US
Assignee:
Talecris Biotherapeutics, Inc. - Research Triangle Park NC
International Classification:
A61K038/48
US Classification:
424 9464
Abstract:
Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus. The method is applicable to the dissolution of thrombi in artificial devices, e. g. , hemodialysis grafts.
Il-2 Selective Agonists And Antagonists
US Patent:
7105653, Sep 12, 2006
Filed:
Apr 17, 2004
Appl. No.:
10/826809
Inventors:
Armen B. Shanafelt - Carmel IN, US
Jeffrey M. Greve - Berkeley CA, US
Gary Jesmok - Richmond CA, US
Kenneth Lembach - Danville CA, US
Gayle D. Wetzel - Martinez CA, US
Jeffrey M. Greve - Berkeley CA, US
Gary Jesmok - Richmond CA, US
Kenneth Lembach - Danville CA, US
Gayle D. Wetzel - Martinez CA, US
International Classification:
C12N 5/10
C12N 15/26
C12N 15/63
C12N 15/26
C12N 15/63
US Classification:
536 235, 435 711, 435 712, 4352523, 4353201, 435 6952
Abstract:
The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
Methods Of Treatment Using Heat-Treated Igm Antibody Preparations
US Patent:
5612033, Mar 18, 1997
Filed:
Jun 6, 1995
Appl. No.:
8/468221
Inventors:
Grace C. Tsay - Walnut Creek CA
Gary Jesmok - Pinole CA
Gary Jesmok - Pinole CA
Assignee:
Bayer Corporation - Berkeley CA
International Classification:
A61K 39395
C07K 1606
C07K 1606
US Classification:
4241771
Abstract:
Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding properties and activate complement when bound to antigen. Preferred product includes at least 20% by weight IgM in an IgM/IgG antibody mixture. Heating is done at a temperature within the range of about 40. degree. C. to 62. degree. C. , preferably about 45. degree. to 55. degree. C. , in a solution having an acid pH (preferably 4. 0 to 5. 0) for at least about 10 minutes.
Heat-Treated Igm Antibody Preparations
US Patent:
5510465, Apr 23, 1996
Filed:
Jul 26, 1993
Appl. No.:
8/096398
Inventors:
Grace C. Tsay - Walnut Creek CA
Gary Jesmok - Pinole CA
Gary Jesmok - Pinole CA
Assignee:
Bayer Corporation - Elkhart IN
International Classification:
C07K 1606
A61K 39395
A61K 39395
US Classification:
5303891
Abstract:
Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding properties and activate complement when bound to antigen. Preferred product includes at least 20% by weight IgM in an IgM/IgG antibody mixture. Heating is done at a temperature within the range of about 40. degree. C. to 62. degree. C. , preferably about 45. degree. to 55. degree. C. , in a solution having an acid pH (preferably 4. 0 to 5. 0) for at least about 10 minutes.
Heat Treatment Of Igm-Containing Immunoglobulins To Eliminate Non-Specific Complement Activation
US Patent:
5256771, Oct 26, 1993
Filed:
Apr 3, 1990
Appl. No.:
7/504161
Inventors:
Grace C. Tsay - Walnut Creek CA
Gary Jesmok - Pinole CA
Gary Jesmok - Pinole CA
Assignee:
Miles Inc. - Berkeley CA
International Classification:
A61K 39395
C07K 312
C07K 1506
C07K 312
C07K 1506
US Classification:
5303905
Abstract:
Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding properties and activate complement specific antigen binding properties and activate complement when bound to antigen. Preferred product includes at least 20% by weight IgM in an IgM/IgG antibody mixture. Heating is done at a temperature within the range of about 40. degree. C. to 62. degree. C. , preferably about 45. degree. to 55. degree. C. , in a solution having an acid pH (preferably 4. 0 to 5. 0) for at least about 10 minutes.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.